Hemostats Market By Product Type (Absorbable Hemostats {Gelatin-based, Collagen-based, Oxidized Regenerated Cellulose (ORC), Polysaccharide-based}, Non-absorbable Hemostats {Bone Wax, Microfibrillar Collagen, Chitosan-based}), By Application (General Surgery, Cardiovascular Surgery, Orthopedic Surgery, Neurosurgery, Gynecological Surgery, Urological Surgery, ENT Surgery, Others), By Form (Powder, Foam, Gel, Sheet, Sponge), By Material (Collagen, Gelatin, Cellulose, Chitosan, Synthetic Polymers), and By End User (Hospitals, Ambulatory Surgical Centers (ASCs), Clinics, Specialty Surgical Centers), Global Market Size, Segmental analysis, Regional Overview, Company share analysis, Leading Company Profiles And Market Forecast, 2025 – 2035

---

What trends will shape Hemostats Market in the coming years?

The Hemostats Market accounted for USD 3.01 Billion in 2024 and USD 3.21 Billion in 2025 is expected to reach USD 6.14 Billion by 2035, growing at a CAGR of around 6.69% between 2025 and 2035. The haemostat market is the collective of industries around the world dedicated to the manufacturing and distribution of haemostatic agents and devices to help with haemostasis in surgical practices or trauma patients. Haemostats find utility in several surgical specialities, such as cardiovascular surgery, cardiac surgery, orthopaedic surgery or orthopaedics, and dental surgery. They work either by facilitating the formation of clots, applying a seal to blood vessels, or even by mechanical compression. The products that the market entails are mechanical hemostats (clamps and forceps), active agents (thrombin-based), and absorbable materials. The dynamics in this market are due to the increasing surgical numbers, the development of surgical practices, and the growing requirement for less invasive procedures.

What do industry experts say about the Hemostats market trends?

“Hemostats remain an essential part of surgical practice, allowing surgeons to control bleeding quickly and precisely. Their design innovations over the years have greatly improved surgical efficiency and patient safety.”

• Dr. Atul Gawande, MD, MPH – Surgeon, Author, and Professor, Harvard Medical School

“The proper use of hemostats is critical in both trauma and elective surgeries. They not only control bleeding but also provide better visualization, which reduces intraoperative complications.”

• Dr. Richard J. Korthuis, MD, MPH – Professor of Medicine, Oregon Health & Science University

Which segments and geographies does the report analyze?

What are the key drivers and challenges shaping the Hemostats market?

How does increasing elderly population and surgical procedures boost hemostats demand?

The rising prevalence of the aged population is a major factor in promoting the growth of haemostats, as older age groups are prone to surgeries caused by the related cases of heart disorders, cancers, and orthopaedic diseases. Bureau data show that in 2020, approximately 16% of the population in the United States was aged 65 or above, with this cohort usually receiving more surgeries than the younger population. There are also indications that more than 50 million surgical operations occur in the United States each year, and many of these surgical operations utilise haemostatic agents to stop the bleeding and enhance surgical outcomes.

The increased number of ageing people and a large number of surgeries pose a considerable demand for haemostats that are important in handling blood loss and improving patient safety during surgical procedures. Further, the deployment of modern surgical practices and the use of minimally invasive surgery also contribute to the heightened use of haemostatic products to guarantee bleeding management. The trend reveals the underlying importance of haemostats in the operation of successful surgical procedures within the different medical disciplines.

Why does rising awareness about bleeding control improve hemostats adoption rates?

An increase in awareness against bleeding control would become a major factor contributing to the increased utilisation of haemostats, as the importance of timely treatment of haemorrhagic events is highlighted. Learning scientifically proven methods of preventing bleeding deaths through educational campaigns, e.g., the Stop the Bleed programme sponsored by the U.S. Department of Homeland Security, has expanded awareness of how effective and life-saving practical bleeding control can be among medical personnel and the population at large.

The CDC estimates uncontrolled bleeding as a major cause of traumatic preventable death, and there is a need to get effective solutions, such as haemostats. Such realisation is pushing hospitals, first responders, and civilians to embrace the use of such highly advanced haemostatic products, which can result in more effective and faster blood clotting than traditional methods. The American College of Surgeons, among others, has also campaigned to involve haemostatic agents in the treatment of trauma. Similar to the cause and effect connection with the supply and consumption of haemostats in the clinical and emergency settings, the higher the education on bleeding emergencies, the higher the aspects of increases in demand and usage of haemostats.

How do safety concerns and allergic reactions limit hemostats usage among patients?

The risk of safety and allergic reactions considerably restricts the application of haemostats in patients. Most haemostatic agents, particularly those based on animal proteins or human proteins, are associated with the risk of immunogenic responses, i.e., an immune response that can range from hypersensitivity or allergies, and complicate patient care. There are documented adverse reactions to surgical haemostatic products, with an anaphylactic reaction being rare but severe. Moreover, the response of bodily tissues to the propensity of the agent to localised inflammation and tissue necrosis may also be spoken by some patients.

According to the Centres for Disease Control and Prevention (CDC), the risks of infection that are associated with biologically derived hemostats are more difficult to monitor. This poses safety problems that necessitate deliberate selection and prevent widespread use, especially in patients who have known allergies or patients whose immune systems are weakened. Therefore, the advantages of haemostatic efficacy achieved may be weighed against the possible adverse outcomes, limiting their administration to specific populations of patients.

How can surgeon training and digital platforms improve hemostat adoption rates?

The combination of a surgeon training programme and digital platforms could positively support the rate of acceptance of the technology of haemostats through familiarisation, reduction in fear, and comfort by health experts. Experiential learning curricula that are complemented with virtual simulation and e-learning materials allow surgeons to train in the deployment of haemostats without risk of injury, acquire skills, and minimise the likelihood of practice-related errors.

As the report prepared by the Association of American Medical Colleges (AAMC) indicates, simulation-based education used in the process of medical training enhances retention of clinical skills by as much as 30%, which serves to illustrate the power of digital training tools. On digital platforms, it is much more convenient to organise constant further training and be informed in real time about new haemostatic technologies and methods, thereby enabling surgeons to keep up with advances.

The National Institutes of Health (NIH) confirms they strongly support the notion that continuous professional education is directly linked with the patient Chen and Bakar's 31 outcomes and the rates of procedure adoption in general. Combining formal surgeon training with readily available electronic materials, hospitals may move faster on haemostat use, ultimately to lower intraoperative haemorrhagic complications and enhance surgery efficacy.

Why do emerging markets and healthcare infrastructure growth offer expansion opportunities?

In emerging economies, the haemostat market has a massive growth potential in terms of rising healthcare investments and a high rate of surgery prevalence. Most of the developing nations, like India and Brazil, are quickly transforming their healthcare infrastructures due to the government efforts of upgrading the hospital capacities and access to surgical care. The World Health Organisation (WHO) predicts a large growth in the surgical volume globally, with low- and middle-income countries experiencing the brunt of this disparity, with high unmet surgical needs.

Furthermore, the World Bank forecasts an increase in healthcare spending in emerging economies at a CAGR of 6-7% in the next ten years. The increase in insurance cover and government spending on health services in these locations earmarks the need for quality surgical equipment that reduces complications and enhances good results. Owing to that, the Hemostats Market can capitalise on these trends and ensure effective growth by fulfilling the growing surgical needs and facility development in the developing economies.

What are the key market segments in the Hemostats industry?

Based on the product type, the Hemostats Market is classified into Absorbable Hemostats and Non-absorbable Hemostats. The Absorbable Hemostats segment presents the biggest market of the Hemostats Market. Such dominance is fuelled by the fact that they are naturally broken down in the body and utilised, thereby preventing the need to undertake surgical removal procedures and also minimising post-surgical complications. Their application in many procedures, and especially in minimally invasive procedures and cardiovascular surgeries, increases patient outcomes because it leads to faster healing and decreases the chances of contracting an infection. The rising population using biocompatible and safe medical products also influences the use of absorbable haemostats, thus significantly contributing to the market.
 

The general surgery segment holds the most important position in the haemostat market. This is prominent owing to the high number and type of general surgical operations undertaken across the globe, where excellent control of bleeding that such operations may involve is vital. Haemostats have become quite popular during such surgeries with the aim of reducing blood loss, improving visibility during the surgery, and making patient safety a priority. Its wide use in various kinds of general surgeries, such as abdominal and soft tissue procedures, contributes to its high popularity in the haemostat market.

Based on the application, the Hemostats Market is classified into General Surgery, Cardiovascular Surgery, Orthopedic Surgery, Neurosurgery, Gynecological Surgery, Urological Surgery, ENT Surgery, and Others.

Which regions are leading the Hemostats market, and why?

The North American hemostat market is dominant because of the establishment of healthcare infrastructure, thriving healthcare spending, and the presence of key market players. The affluence of the region is characterised by advanced surgical techniques and the high number of surgeries that boost the demand for effective blood loss control, such as haemostats. Research and development-based intensive focus and a faster implementation of innovative medical technology contribute to market growth. If their reimbursement policies and high regulatory standards are favourable, the availability of safe and effective products is guaranteed.

The growing geriatric population and the rising number of the chronically ailing population also contribute to surgical procedures, thus increasing the need for haemostatic agents in North America. Educating the healthcare professionals about the advantages of performing minimally invasive surgeries also helps drive this market. Moreover, the combined work of manufacturers and healthcare providers can result in the enhancement of product accessibility and patient outcomes in the region.

The Asia Pacific haemostats market is leading owing to the ability of the region to collectively contribute to the market through a combination of a huge and ageing population, a rise in surgical procedures, and augmented healthcare investments. Several nations, such as China, India, and Japan, are experiencing tremendous growth in both government and non-government healthcare sectors, which has culminated in the increased demand for complex surgical equipment and wound care products. Moreover, the increasing cases of chronic diseases, traumas, and road accidents further stimulate the requirement to have efficient solutions for managing blood.

Local production, advancement of government policies, and medical tourism in countries such as Thailand or Singapore are also factors in market leadership in the region. Besides, the availability and affordable manufacturing of qualified healthcare providers are the key reasons why the Asia Pacific is swiftly becoming the global medical device hub. Innovation and inclination to use a minimally invasive surgical procedure in the region are gaining momentum, which is fast driving the demand for advanced haemostatic products, which is why the region is perceived as a leader in the market.

What does the competitive landscape of the Hemostats market look like?

The haemostat market is very competitive, with a few global healthcare magnates and specialised companies. Major competitors like Baxter International, Johnson & Johnson, Becton Dickinson, Medtronic, and Integra LifeSciences are committed to research and development-related expenditure to develop enhanced haemostatic solutions to help ensure positive surgical interventions.

The recent trends include mergers and acquisitions as strategic alliances with a view to increasing product portfolios and coverage. For instance, Medtronic has recently added haemostatic products to its portfolio with the acquisition of smaller biotech companies specialising in bioactive material. In the interim, Baxter has been busy enhancing the safety and efficacy of its current breadth of solutions via clinical trials and regulatory approvals.

Emergent players such as CryoLife and Haemostasis LLC are also making cuts through the introduction of novel, minimally invasive haemostatic technologies. Overall, the competition in the market is influenced by innovative business, effective partnerships, and a high focus on unmet clinical needs related to bleeding control during surgery.

Hemostats Market, Company Shares Analysis, 2024

To explore in-depth analysis in this report - Request Sample Report

Which recent mergers, acquisitions, or product launches are shaping the Hemostats industry?

• In October 2024, Arch Therapeutics received regulatory approval to market its AC5® Advanced Wound System and AC5® Topical Hemostat in the United States and Europe. These medical devices were developed using self-assembling peptide (SAP) technology. The technology was designed to enhance hemostasis and improve bleeding control. The products aimed to support use in both surgical and trauma care settings.

Report Coverage:

By Product Type

• Absorbable Hemostats
  • Gelatin-based
  • Collagen-based
  • Oxidized Regenerated Cellulose (ORC)
  • Polysaccharide-based
• Non-absorbable Hemostats
  • Bone Wax
  • Microfibrillar Collagen
  • Chitosan-based

By Application

• General Surgery
• Cardiovascular Surgery
• Orthopedic Surgery
• Neurosurgery
• Gynecological Surgery
• Urological Surgery
• ENT Surgery
• Others

By Form

• Powder
• Foam
• Gel
• Sheet
• Sponge

By Material

• Collagen
• Gelatin
• Cellulose
• Chitosan
• Synthetic Polymers

By End User

• Hospitals
• Ambulatory Surgical Centers (ASCs)
• Clinics
• Specialty Surgical Centers

By Region

North America

• U.S.
• Canada

Europe

• U.K.
• France
• Germany
• Italy
• Spain
• Rest of Europe

Asia Pacific

• China
• Japan
• India
• Australia
• South Korea
• Singapore
• Rest of Asia Pacific

Latin America

• Brazil
• Argentina
• Mexico
• Rest of Latin America

Middle East & Africa

• GCC Countries
• South Africa
• Rest of Middle East & Africa

List of Companies:

• Baxter International Inc.
• Pfizer Inc.
• B. Braun Melsungen AG
• Integra LifeSciences Corporation
• Medtronic plc
• CSL Behring
• Gelita Medical GmbH
• Grifols, S.A.
• Becton, Dickinson and Company (BD)
• Advanced Medical Solutions Group plc
• Johnson & Johnson Services, Inc.
• Teleflex Incorporated
• Stryker Corporation
• Hemostasis LLC
• CryoLife, Inc.

Frequently Asked Questions (FAQs)